{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:25:14Z","timestamp":1787275514212,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05801-z","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:16:16Z","timestamp":1787274976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of combined metformin plus progestin therapy versus progestin monotherapy in endometrial hyperplasia: a randomized clinical trial"],"prefix":"10.1007","author":[{"given":"Rahele Jabbari","family":"Morouei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alishvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Dadashaliha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Ranjbaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cena","family":"Aram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Ebrahimi","family":"Rigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijeh","family":"Elmizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"6","key":"5801_CR1","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00404-024-07416-2","volume":"309","author":"L Adamyan","year":"2024","unstructured":"Adamyan L, Pivazyan L, Isaeva S, Shapovalenko R, Zakaryan A (2024) Metformin and progestins in women with atypical hyperplasia or endometrial cancer: systematic review and meta-analysis. Arch Gynecol Obstet 309(6):2289\u20132305","journal-title":"Arch Gynecol Obstet"},{"key":"5801_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193143","author":"E Boureka","year":"2025","unstructured":"Boureka E, Tsakiridis I, Kapetanios G, Michos G, Giouleka S, Liberis A et al (2025) Management of endometrial hyperplasia: a comparative review of guidelines. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17193143","journal-title":"Cancers (Basel)"},{"issue":"22","key":"5801_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14222471","volume":"14","author":"A-J Chou","year":"2024","unstructured":"Chou A-J, Bing R-S, Ding D-C (2024) Endometrial atypical hyperplasia and risk of endometrial cancer. Diagnostics (Basel) 14(22):2471","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"5801_CR4","first-page":"CD012214","volume":"10","author":"NS Clement","year":"2017","unstructured":"Clement NS, Oliver TR, Shiwani H, Sanner JR, Mulvaney CA, Atiomo W (2017) Metformin for endometrial hyperplasia. Cochrane Database Syst Rev 10(10):CD012214","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"5801_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0034-1396256","volume":"75","author":"G Emons","year":"2015","unstructured":"Emons G, Beckmann MW, Schmidt D, Mallmann P (2015) New WHO classification of endometrial hyperplasias. Geburtshilfe Frauenheilkd 75(2):135\u2013136","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"11","key":"5801_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.47895\/amp.v58i11.8155","volume":"58","author":"PAA Factor","year":"2024","unstructured":"Factor PAA, Pasamba KC (2024) Metformin as an adjunct to progestin therapy in endometrial hyperplasia and early-stage endometrial cancer: a systematic review and meta-analysis of randomized controlled trials. Acta Med Philipp 58(11):62\u201371","journal-title":"Acta Med Philipp"},{"issue":"1","key":"5801_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18010148","volume":"18","author":"A Galani","year":"2026","unstructured":"Galani A, Stavros S, Moustakli E, Potiris A, Zikopoulos A, Anagnostaki I et al (2026) Endometrial hyperplasia: current insights into epidemiology, risk factors, and clinical management. Cancers 18(1):148","journal-title":"Cancers"},{"key":"5801_CR8","doi-asserted-by":"crossref","unstructured":"Guan J, Chen X-J  (2022) The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Front  Endocrinol 13","DOI":"10.3389\/fendo.2022.1041535"},{"issue":"1","key":"5801_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41467-025-67087-8","volume":"17","author":"PA Konstantinopoulos","year":"2025","unstructured":"Konstantinopoulos PA, Zhou N, Penson RT, Le TV, Campos S, Krasner C et al (2025) Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial. Nat Commun 17(1):395","journal-title":"Nat Commun"},{"key":"5801_CR10","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2147\/IJWH.S477045","volume":"16","author":"D Kuai","year":"2024","unstructured":"Kuai D, Wei J, Li M, Chen L, Zhang D, Li X et al (2024) Weight-loss and metformin-use improve the reversal rate in patients with endometrial hyperplasia. Int J Womens Health 16:1815\u20131828","journal-title":"Int J Womens Health"},{"issue":"1","key":"5801_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.62347\/EKGS3484","volume":"18","author":"J Li","year":"2026","unstructured":"Li J, Hou Y, Liao D (2026) Metformin combined with progesterone improves efficacy and reduces adverse reactions in early endometrial cancer. Am J Transl Res 18(1):574\u2013582","journal-title":"Am J Transl Res"},{"key":"5801_CR12","doi-asserted-by":"crossref","unstructured":"Li X, Fan Y, Wang J, Zhou R, Tian L, Wang Y, et al (2021) Insulin resistance and metabolic syndrome increase the risk of relapse for fertility preserving treatment in atypical endometrial hyperplasia and early endometrial cancer patients. Front Oncol 11","DOI":"10.3389\/fonc.2021.744689"},{"issue":"5","key":"5801_CR13","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.fmre.2023.07.008","volume":"5","author":"J Liu","year":"2025","unstructured":"Liu J, Zhou J, Wang Y, Xue F, Chen X, Chen G et al (2025) Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer. Fundamental Research 5(5):2330\u20132342","journal-title":"Fundamental Research"},{"key":"5801_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246210","author":"M Lv","year":"2022","unstructured":"Lv M, Chen P, Bai M, Huang Y, Li L, Feng Y et al (2022) Progestin resistance and corresponding management of abnormal endometrial hyperplasia and endometrial carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14246210","journal-title":"Cancers (Basel)"},{"issue":"22","key":"5801_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e40285","volume":"10","author":"X Ma","year":"2024","unstructured":"Ma X, Wu X, Du J, Sun H (2024) Evolution of endometrial cancer incidence patterns in Hong Kong: a three-decade analysis with future projections. Heliyon 10(22):e40285","journal-title":"Heliyon"},{"issue":"7","key":"5801_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27747","volume":"66","author":"TP Miller","year":"2019","unstructured":"Miller TP, Fisher BT, Getz KD, Sack L, Razzaghi H, Seif AE et al (2019) Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. Pediatr Blood Cancer 66(7):e27747","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"5801_CR17","volume":"9","author":"T Mittermeier","year":"2020","unstructured":"Mittermeier T, Farrant C, Wise MR (2020) Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev 9(9):Cd012658","journal-title":"Cochrane Database Syst Rev"},{"key":"5801_CR18","doi-asserted-by":"crossref","unstructured":"Mitsuhashi A, Habu Y, Kobayashi T, Kawarai Y, Ishikawa H, Usui H, et al  (2019) Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. J Gynecol Oncol 30(6)","DOI":"10.3802\/jgo.2019.30.e90"},{"key":"5801_CR19","doi-asserted-by":"crossref","unstructured":"Santos Fortes Dos Reis VM, Ramos FM, de Oliveira HL, Machado FD, Hartke S, Machado-Weber A, et al (2025) Effects of metformin treatment against endometrial cancer cells cultured in vitro or grafted into female Balb\/C nude mice: insights into cell response and IGF-1R and PI3K\/AKT\/mTOR signaling pathways. Cell Biochem Biophys 83(4):5227\u201345","DOI":"10.1007\/s12013-025-01840-0"},{"key":"5801_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-11-32","volume":"11","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Trials 11:32","journal-title":"Trials"},{"key":"5801_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1139858","volume":"14","author":"F Shao","year":"2023","unstructured":"Shao F, Li Y, Zhao Y (2023) Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. Front Endocrinol 14:1139858","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"5801_CR22","volume":"5","author":"H Shiwani","year":"2024","unstructured":"Shiwani H, Clement NS, Daniels JP, Atiomo W (2024) Metformin for endometrial hyperplasia. Cochrane Database Syst Rev 5(5):Cd012214","journal-title":"Cochrane Database Syst Rev"},{"key":"5801_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122801","author":"D \u0160i\u0161ljagi\u0107","year":"2024","unstructured":"\u0160i\u0161ljagi\u0107 D, Bla\u017eeti\u0107 S, Heffer M, Vranje\u0161 Dela\u0107 M, Muller A (2024) The interplay of uterine health and obesity: a comprehensive review. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12122801","journal-title":"Biomedicines"},{"issue":"3","key":"5801_CR24","first-page":"107","volume":"16","author":"K Sobczuk","year":"2017","unstructured":"Sobczuk K, Sobczuk A (2017) New classification system of endometrial hyperplasia WHO 2014 and its clinical implications. Prz Menopauzalny 16(3):107\u2013111","journal-title":"Prz Menopauzalny"},{"issue":"6","key":"5801_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2020.101863","volume":"50","author":"A Tehranian","year":"2021","unstructured":"Tehranian A, Ghahghaei-nezamabadi A, Arab M, Khalagi K, Aghajani R, Sadeghi S (2021) The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial. J Gynecol Obstet Hum Reprod 50(6):101863","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"3-5","key":"5801_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jsbmb.2010.12.006","volume":"126","author":"Y Xie","year":"2011","unstructured":"Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y et al (2011) Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 126(3\u20135):113\u2013120","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"5801_CR27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/1471-0528.16108","volume":"127","author":"BY Yang","year":"2020","unstructured":"Yang BY, Gulinazi Y, Du Y, Ning CC, Cheng YL, Shan WW et al (2020) Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG 127(7):848\u2013857","journal-title":"BJOG"},{"issue":"5","key":"5801_CR28","first-page":"4410","volume":"18","author":"HL Yang","year":"2018","unstructured":"Yang HL, Chang KK, Mei J, Zhou WJ, Liu LB, Yao L et al (2018) Estrogen restricts the apoptosis of endometrial stromal cells by promoting TSLP secretion. Mol Med Rep 18(5):4410\u20134416","journal-title":"Mol Med Rep"},{"issue":"38","key":"5801_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039619","volume":"103","author":"Y Yao","year":"2024","unstructured":"Yao Y, Xu S, Wang T, Jiang R (2024) Efficacy of drugs treatment in patients with endometrial hyperplasia with or without atypia: a systematic review and network meta-analysis. Medicine (Baltimore) 103(38):e39619","journal-title":"Medicine (Baltimore)"},{"key":"5801_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-026-04352-y","author":"J Ye","year":"2026","unstructured":"Ye J, Mm XQ, Qi X (2026) Fertility-preserving treatment for endometrial atypical hyperplasia and endometrial cancer: a systematic review and meta-analysis. BMC Womens Health. https:\/\/doi.org\/10.1186\/s12905-026-04352-y","journal-title":"BMC Womens Health"},{"issue":"2","key":"5801_CR31","doi-asserted-by":"publisher","first-page":"e2558205","DOI":"10.1001\/jamanetworkopen.2025.58205","volume":"9","author":"TT Yen","year":"2026","unstructured":"Yen TT, Hsieh TYJ, Lee GY, Toy EP, Wei JC, Tanner EJ (2026) GLP-1 receptor agonists plus progestins and endometrial cancer risk in nonmalignant uterine diseases. JAMA Netw Open 9(2):e2558205","journal-title":"JAMA Netw Open"},{"issue":"12","key":"5801_CR32","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/cas.13083","volume":"107","author":"J Zou","year":"2016","unstructured":"Zou J, Hong L, Luo C, Li Z, Zhu Y, Huang T et al (2016) Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway. Cancer Sci 107(12):1806\u20131817","journal-title":"Cancer Sci"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05801-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T01:16:18Z","timestamp":1787274978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05801-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":32,"alternative-id":["5801"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05801-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of Qazvin University of Medical Sciences (IR.QUMS.REC.1401.191). The trial was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of anonymized data was obtained from all participants.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT in order to enhance thereadability of the text and check the grammar. After using this tool, the authors reviewed andedited the content as needed and take full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"Declaration of generative AI in scientific writing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}